

Review

Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review

Daniel Shu Wei Ting MMed(Ophth) PhD,^{1,2} Gemmy Chui Ming Cheung FRCOphth^{1,2,3} and Tien Yin Wong PhD FRANZCO^{1,2,3}

¹Singapore National Eye Center, Singapore Health Service (SingHealth), ²Singapore Eye Research Institute, and ³Duke-NUS Graduate Medical School, Singapore, Singapore

ABSTRACT

Diabetes retinopathy (DR) is a leading cause of vision loss in middle-aged and elderly people globally. Early detection and prompt treatment allow prevention of diabetes-related visual impairment. Patients with diabetes require regular follow-up with primary care physicians to optimize their glycaemic, blood pressure and lipid control to prevent development and progression of DR and other diabetes-related complications. Other risk factors of DR include higher body mass index, puberty and pregnancy, and cataract surgery. There are weaker associations with some genetic and inflammatory markers. With the rising incidence and prevalence of diabetes and DR, public health systems in both developing and developed countries will be faced with increasing costs of implementation and maintenance of a DR screening program for people with diabetes. To reduce the impact of DR-related visual loss, it is important that all stakeholders continue to look for innovative ways of managing and preventing diabetes, and optimize cost-effective screening programs within the community.

INTRODUCTION

Diabetes mellitus (DM) is one of the world's fastest growing chronic diseases and a leading cause of acquired vision loss.¹ According to the World Health Organization, it is estimated that the total number of people with diabetes will double from 171 million in 2000 to 366 million by 2030.² Diabetic retinopathy

(DR), a specific microvascular complication of DM, remains the leading cause of acquired vision loss worldwide in middle-aged and therefore economically active people.^{1,3,4} With the increasing number of people with diabetes, the number of DR and vision-threatening DR (VTDR), which includes severe non-proliferative DR, proliferative DR (PDR) and diabetic macular edema (DME), has been estimated to rise to 191.0 million and 56.3 million, respectively by 2030.⁵

Over the past few decades, there have been major advances made in understanding the epidemiology of DR, systemic control of DM to prevent DR development and progression, clinical assessment, diagnosis and management of DR and VTDR. There is widespread knowledge that screening, early detection and prompt treatment of VTDR allow prevention of diabetes-related visual impairment.⁶ Randomized controlled trials have shown that early treatment can reduce an individual's risk of severe visual loss by 57%.⁷ However, DR screening services in developing and developed countries remain patchy, and are constantly challenged by unclear guidelines on the most appropriate method to screen (e.g. clinical examination vs fundus photography), and the increasing resources needed for implementation and maintenance of a comprehensive DR screening programs.⁸ Thus, DR is an increasingly significant major public health problem, especially in many middle-to-low income countries where access to trained eye-care professionals and secondary and tertiary eye-care services (e.g. access to laser and intra-vitreous therapies) may be suboptimal. It is,

■ **Correspondence:** Prof Tien Yin Wong, Singapore National Eye Center, 11 Third Hospital Avenue, Singapore 168751, Singapore. Email: tien_yin_wong@nuhs.edu.sg

Received 12 July 2015; accepted 21 December 2015.

Competing/conflicts of interest: None.

Funding sources: None.

therefore important that all public and private stakeholders continue to look for innovative ways of managing DM, improve access to DR screening, and plan and optimize cost-effective screening programs within the community.

This review article aims to explore the global prevalence and incidence of DR, the major risk factors for DR, DR screening practices worldwide and the challenges in public health in implementing appropriate DR screening and management strategies.

GLOBAL EPIDEMIOLOGY OF DR

Global prevalence of DR

According to the World Health Organization (WHO), it is estimated that DR accounts for 4.8% of the number of cases of blindness (37 million) worldwide.⁹ A pooled analysis of 22 896 people with diabetes from 35 population-based studies in the U.S., Australia, Europe and Asia (between 1980–2008) showed that the overall prevalence of any DR (in T1DM and T2DM) was 34.6% (95% CI 34.5–34.8), with 7% (6.9–7.0) VTDR.¹⁰

Type 1 Diabetes (T1DM)

The prevalence of DR was reported to range from 10 to 50%, depending on the population and methods used to screen for DR, and the duration of diabetes.¹¹ Given the significant variation in management of T1DM in different health care systems, the comparison of prevalence of T1DM-related DR should be analysed with caution. The EURODIAB study, a multicentre study involving 31 clinics in 16 European countries, reported the prevalence of DR among T1DM patients ranged from 25% in Austria to 60% in Portugal.¹² In 2004, the pooled data from two US studies of T1DM (Wisconsin Epidemiologic Study of Diabetic Retinopathy – WESDR, and the New Jersey 725 study) found the prevalence for any DR and VTDR of 82% and 32%, respectively.¹³ The DR prevalence among the T1DM was reported to be lower in Asia with the lowest prevalence in India (13.4%),¹⁴ followed by China (14%).¹⁵ In Australia and New Zealand, the DR prevalence rate ranged from 25% to 42%.^{16–19} The prevalence of DME is related to the disease duration, with low rates of DME within 5 years of T1DM diagnosis, increasing to 29% at 20 years.²⁰ The prevalence was found to vary over time, likely because of the improved health care for T1DM over time and the incidence studies can provide better insights into these temporal changes.

Type 2 Diabetes (T2DM)

The overall prevalence DR and VTDR in T2DM were 25.2% and 6.9%, respectively.¹⁰ According to Liverpool Diabetic Eye Study²¹ and the United Kingdom

Prospective Diabetes Study (UKPDS),²² the DR prevalence for T2DM in United Kingdom ranged from 25% to 27%. The prevalence of DR in other European countries such as Sweden, Denmark and Italy were slightly higher, ranging from 30% to 40%.^{23–25} In the United States, there were several large population-based studies reporting on DR prevalence and incidence (San Luis Valley Study,²⁶ Los Angeles Latino Eye Study [LALES],²⁷ Multi-ethnic Study of Atherosclerosis [MESA]²⁸ and Veterans Affairs Diabetes Trial [VADT]²⁹). The prevalence of DR ranged from 30 to 50%, with the highest prevalence seen in the Hispanic population.³⁰ Various population-based studies in Australia (e.g. AusDiab study,³¹ Blue Mountains Eye Study [BMES],³² Melbourne Visual Impairment Project [MVIP]³³ and Newcastle Diabetic Retinopathy Study)^{34,35} reported DR and VTDR prevalence rate of 22%–35% and 1.2%–7.1%, respectively among T2DM patients.

In the past, DR prevalence had been relatively low in Asia.^{36,37} In China, the prevalence of DR in T2DM ranged from 28% to 43%.^{38,39} Because of poorer access to screening services, the prevalence of DR was higher in the rural than the urban areas in China.³⁸ On the contrary, the Indians who lived in urban areas had higher prevalence of diabetes (28.2% vs 10.4%) and DR (18% vs 10.3%) as compared to the rural Indians.^{37,40} In a multi-ethnic Asian population-based study, Chiang et al. also reported racial differences in the prevalence of diabetes but not diabetic retinopathy, with the highest prevalence seen in the Indian (28.9%) and, followed by the Malay (24.8%) and Chinese (20.1%).⁴¹

The Singapore Indian Eye Study reported a higher DR prevalence (33%) amongst the migrant Indians who lived in Singapore (a newly urbanized Asian country) than those living in urban India.⁴² It had been postulated that new migrant Indians in Singapore frequently experience new lifestyle patterns and dietary habits with calorie-dense/lower-fiber foods, further complicated by the psychological stressors, shortage of financial resources and/or other unmeasured inequalities.

Incidence and Progression of DR

Type 1 Diabetes (T1DM)

In Europe, 50% of T1DM with no DR at baseline had been shown to develop retinopathy by 5 to 7 years, and 9% with mild NPDR would develop PDR by 5 years.⁴³ On the other hand, the US WESDR showed the 10-year DR incidence in T1DM was 74%, increasing to 97% after 25 years. Of those who had any DR at baseline, the incidence of DR progression (2+ steps progression on Early Treatment Diabetic Retinopathy Study [ETDRS] scale) was 64% at 10 years and 83%

at 25 years.⁴⁴ Annual estimates of the 25-year WESDR study have shown a decline in PDR and DME incidence in the latter half of the study compared to the first 12 years.^{44,45}

Type 2 Diabetes (T2DM)

In UK, the 5-year cumulative DR incidence in T2DM was 4%, rising to 16.4% after 10-years follow-up (from no retinopathy to pre-proliferative retinopathy).⁴⁶ The annual incidence of retinopathy in US (LALES) was 7.1%,²⁷ similar to WESDR (8.6%)⁴⁴ and the Barbados Incidence Study of Eye Diseases (7.5%),⁴⁷ but was higher than the rates found in the non-US studies, predominantly on white population. In Australia, the BMES reported the 5-year DR cumulative-incidence and DR progression (1+ ETDRS steps) were 22.2% and 25.9%.⁴⁸ In Hong Kong, the 4-year cumulative DR incidence, DR progression (2+ ETDRS steps) and VTDR incidence for T2DM were 15.2%, 45.5% and 0.03%, respectively.⁴⁹

Declining Prevalence and Incidence of DR

With the increased awareness of DR risk factors, better glycaemic control and access to the screening programs in the community, there is a decline in the prevalence and incidence of DR in the developed countries such as US, Australia and the European countries. A systematic review and meta-analysis covering 1975–2008 showed a significant decline in prevalence of DR, as compared to the rates before 1985.⁵⁰ The 10-year incidence of PDR and severe visual loss (SVL) were substantially lower in the studies published between 1986 and 2008, compared to the ones before 1985 (PDR: 6.6% [95% CI: 0.0–18.3%] *vs* 11.5 [0.0–25.7%]; SVL: 2.6 [0.0–7.1%] *vs* 6.0 [0.9–11.1%]).⁵⁰ In US (WESDR), the annual incidence of PDR declined from 3.4% to 1.4% whereas for clinically significant macular edema (CSME), it decreased from 1.0% to 0.4% in T1DM.⁴⁴ There is lack of follow-up study that evaluates the subsequent trend in DR incidence and prevalence over the last 10 years. In addition, more recent rural population-based surveys have shown a higher DR prevalence rate as compared to the metropolitan area, because of limited access to the health care facilities.^{37,40}

Although studies have documented a decline in the incidence of DR among those with T1DM, the DR trend of T2DM patients still remains unknown.

Major Risk Factors For DR

The risk factors of DR can be broadly divided into modifiable and non-modifiable factors (Table 1). The modifiable risk factors include hyperglycaemia, hypertension, hyperlipidemia and obesity (Fig. 1). In contrast, duration of diabetes, puberty and

pregnancy are the non-modifiable risk factors for DR development and progression.

Hyperglycaemia

The Diabetes Control and Complications Trial (DCCT) and UKPDS were the two landmark clinical trials that showed tight glycaemic control [HbA1c value of 7% or less] could reduce the risk of DR development and progression in T1DM and T2DM patients, respectively.^{22,51} In DCCT for T1DM, intensive treatment (median HbA1c of 7.2%) reduced the DR incidence (2+ ETDRS steps) and progression (3+ ETDRS steps) by 76% (95% CI 62–85%) and 54% (95% CI 39–66%), respectively, as compared with conventional treatment (median HbA1c of 9.1%).^{52,53} In T2DM, UKPDS showed a reduction of DR by 25%, including the need for laser photocoagulation.⁵⁴ For every 1% decrease in HbA1c, there was a reduction in 40% of DR development, 25% progression to VTDR, 25% need for laser therapy and 15% blindness in people with diabetes.⁵⁵ In addition, intensive glycaemic control had been shown to reduce the 4-year incidence of DME by 58%.⁵³ These effects (intensive glycaemic control) appeared long lasting because of metabolic memory, also known as 'legacy effect'. It is a term used to describe the beneficial effects of immediate intensive treatment of hyperglycaemia with a sustained benefit with respect to the outcomes for many years, regardless of glycaemia in the later course of diabetes.⁵⁶ It is suggested that early glycaemia normalization can halt hyperglycaemia-induced pathological processes associated with enhanced oxidative stress and glycation of cellular proteins and lipids.⁵⁷ In the Action to Control Cardiovascular Risk in Diabetes Eye study, intensive control of HbA1c (median of 6.4%) decreased the progression of DR from 10.4% to 7.3% over 4 years. However, the results may carry limited clinical relevance as the author defined progression of DR as 3+ ETDRS steps on a 17-point scale, and this finding was only applicable to those with mild retinopathy.

Tight glycaemic control, however, has two potential adverse effects – early worsening of DR and hypoglycaemic attacks.⁵⁵ In DCCT, the intensive group had more T1DM patients with DR worsening (3+ ETDRS) as compared to the conventional treatment group (13.1% *vs* 7.6%, OR 2.1; $P < 0.001$) but this effect was reversed by 18 months.⁵⁸ On the other hand, intensive treatment is also associated with a three-fold risk of hypoglycaemia as compared with conventional treatment in a meta-analysis.⁵⁹ The incidence of severe hypoglycaemia increased by 9.1 episodes per 100 person-years in the intensively treated patients.⁵⁹ In fact, the Action to Control Cardiovascular Risk in Diabetes trial was stopped prematurely after 3.5 years prior to study completion given the fact that the intensive therapy group

Table 1. Risk factors for diabetic retinopathy

Modifiable	
1. HbA1c ⁵⁵	Decrease in every 1% = reduction in 40% of retinopathy, 25% need for retinal laser and 15% of blindness
2. Systolic Blood Pressure ^{44,45}	Decrease in every 10 mmHg = reduction in 35% of retinopathy, 35% need for retinal laser and 50% blindness
3. Hyperlipidemia ⁷³	However, two Asian clinic-based studies did not show association of blood pressure with the incidence and progression of DR DR is associated with triglycerides level whereas DME is associated with LDL, high non-HDL cholesterol and high HDL/LDL ratio
4. Body Mass Index (BMI) ⁷⁸	i. Increased waist-hip ratio, BMI >31 kg (men); BMI >32 kg (women) and BMI <20 kg were associated with increased risk of DR development
Non-modifiable	
1. Puberty ⁸⁸	Post pubertal period has 30% increased risk of DR development and the onset to any DR was faster (2 years shorter) compared to the prepubertal period
2. Pregnancy ^{84,85}	i. Pregnancy could increase risk of DR progression by 2.3 times ii. During postpartum period, 29% would have DR regression iii. Pregnant women with retinopathy is at much higher risk of DR progression, with 47% progression and 50% of those required laser treatment

DME, diabetic macular edema; DR, diabetic retinopathy; HbA1c, glycated haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

(targeting at HbA1c level of less than 6%) has significantly higher mortality rate (hazard ratio, 1.22; 95% CI, 1.01–1.46%, $P=0.04$) and more hypoglycaemic attacks (10.5% vs 3.5%, $P<0.001$), compared with the standard treatment group.⁶⁰

The Action in Diabetes and Vascular Disease (ADVANCE) trial, however, did not demonstrate an increase in risk of death associated with intensive treatment. This was a multicentre trial involving over

10 000 patients with T2DM from 215 collaborating centres in 20 countries from Asia, Australia, Europe and North America. The study found that the HbA1c threshold for macro-vascular events and death was 7%, whereas for micro-vascular events, it was 6.5%.⁶¹ Above these thresholds, the risks increased significantly; every 1% higher HbA1c level was associated with a 38% higher risk of a macro-vascular event, a 40% higher risk of a micro-vascular event




Figure 1. Age-standardized prevalence of any diabetic retinopathy by subgroups of interest, in diabetic subjects aged 20 to 79 years. (Bar indicates prevalence estimate, and capped line indicates 95% confidence interval).¹⁰

and a 38% higher risk of death (all $P < 0.0001$). On the other hand, there was no evidence of achieving additional benefit in reducing macro- and micro-vascular complication below these thresholds, but neither was there clear evidence of harm. Thus, it is crucial to gradually optimize the HbA1c level, aiming for a level between 6.5% and 7% as a long-term management goal, to reduce the incidence of DM-related macro- and micro-vascular complications.

Hypertension

In spite of several epidemiologic studies not finding blood pressure to be a consistent risk factor for DR incidence and progression,^{62–64} multiple randomized controlled trials (RCTs) have demonstrated the benefits of tight blood pressure (BP) control as a major modifiable factor for DR incidence and progression. The UKPDS was the first RCT that showed the importance of tight BP control in reducing retinopathy.²² A total of 1048 hypertensive T2DM patients were randomized into intensive BP control (target systolic/diastolic BP: $<150/85$ mmHg) *versus* conventional control group (target BP: $<180/105$ mmHg). After 9 years of follow-up, patients with tight BP control had a reduction of risk in DR progression by 34% (99%CI 11–50) and visual acuity deterioration by 47% (99%CI 7–70). It has been shown that every 10 mmHg increase in systolic blood pressure was associated with 10% increased risk of early DR and 15% risk of PDR or DME.^{44,45}

On the other hand, anti-hypertensive medications that target the renin-angiotensin system, including angiotensin II receptor antagonists (Candesartan^{65,66} and Losartan⁶⁷) and angiotensin-converting-enzyme inhibitor (Enalapril),⁶⁷ may have additional benefit in slowing DR progression, independent of their hypotensive properties. The Diabetic Retinopathy Candesartan Trials (DIRECT) is a multicentre (309 centres) RCT involving 5231 patients with T1DM or T2DM who were assigned into placebo or 32-mg candesartan, an angiotensin II receptor blocker.^{66,68} In T1DM (DIRECT-Prevent-1, $n = 1421$ and DIRECT-Protect 1, $n = 1905$),⁶⁶ the candesartan group had a marginal effect on lowering incidence of DR (2+ ETDRS steps) by 18%, but not on DR progression (3+ ETDRS steps). In post-hoc analyses, candesartan had been shown to reduce incidence of DR by 35% (hazard ratio 0.65, 95% CI 0.48–0.87%). For T2DM, candesartan reduced DR progression by 13% in the primary outcome, though it was not statistically significant. For secondary outcome, the treatment was shown to increase DR regression by 34% in participants with early retinopathy.^{65,66} The results from DIRECT trial suggested overall beneficial effects of candesartan in reducing retinopathy in T1DM and T2DM (with more obvious effect seen in the early retinopathy group), but

it did not achieve either of the pre-specified primary endpoint of both studies.⁶⁵

In the Renin-Angiotensin System Study, both Enalapril and Losartan were able to reduce risk of DR progression by 65% and 70%, respectively in T1DM, irrespective of their blood pressure lowering actions.⁶⁹ The EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent diabetes Mellitus showed that the Lisinopril, an angiotensin converting enzyme inhibitor, could reduce DR progression by 50% in the first year and 80% in the second year, for those normotensive and normoalbuminuric cases.⁷⁰ However, this study was confounded by the baseline differences in glycaemic level of the treatment *versus* the control group. In addition, neither UKPDS nor the Appropriate Blood pressure Control in Diabetes (ABCD)⁷¹ study reported superiority of angiotensin converting enzyme inhibitor over other anti-hypertensive agents to prevent DR progression. Despite of conflicting results reported on the effect of blood pressure on DR incidence and progression, it is crucial for the primary health care physicians to monitor and optimize the blood pressure for patients with diabetes to prevent DM-related complications in the long term.

Hyperlipidemia

Various studies have reported inconsistent results on the effect of lipid on the development and progression of DR and DME.^{72–74} DCCT showed that the severity of DR correlated positively with increasing triglycerides and inversely with high-density lipoprotein (HDL) in T1DM.⁷⁵ However, there was no association between total cholesterol and DR shown in the Multi-Ethnic Study of Atherosclerosis (MESA)²⁸ and the Chennai Urban Rural Epidemiology Study (CURES) Eye Study.⁷⁴ Of the subset in the lipid panel, triglycerides were shown to be related to the presence of DR and the low-density lipoprotein was related to DME.⁷⁴ In Sankara Nethralaya-Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS), high serum low-density lipoprotein (OR: 2.72), high non-high density lipoprotein cholesterol (OR: 1.99) and high cholesterol ratio (OR: 3.08) were related to DME.⁷³

The subgroup of Action to Control Cardiovascular Risk in Diabetes Eye study has also demonstrated that fenofibrate reduced the DR progression at 4 years in T2DM patients, compared to placebo group (6.5% *vs* 10.2%).⁶⁰ The 5-year Fenofibrate Intervention and Event Lowering in Diabetes study randomized 9795 people with T2DM to daily fenofibrate (a triglyceride-lowering agent) or placebo. The requirement for first laser treatment for all retinopathy was significantly lower in the fenofibrate group than in the placebo group (3.5% *vs* 4.9%, hazard ratio = 0.69; 95% CI 0.56–0.84%,

absolute risk reduction 1.5% [0.7–2.3%], $P=0.0002$). The primary endpoint of 2+ ETDRS progression was similar between the two groups and in the subset of patients without pre-existing retinopathy. In patients with pre-existing retinopathy, fewer patients on fenofibrate had a 2+ ETDRS progression than did those on placebo (3.1% vs 14.6%, $P=0.004$), and fewer had macular edema or laser treatments.⁷⁶ The use of fenofibrate, however, did not seem to correlate with the lipid level in the same study, suggesting that there may be an unknown protective effect of fenofibrate in DM patients.

Body Mass Index (BMI)

Although the influence of BMI on DR had shown conflicting results,^{77–79} more recent reports showed positive correlation of increased BMI and waist to hip ratio (WHR) with increased risk of DR.^{80–82} In WESDR, the association between obesity (BMI >31 for men and >32 for women) *versus* DR severity and progression (2+ ETDRS steps) was not statistically significant ($P > 0.05$).⁷⁸ In the same study, the underweight patients (<20 kg/m²) were associated with increased DR incidence ($P=0.04$),⁷⁸ suggesting that patients with poor overall systemic health may experience concomitant weight loss. The mean BMI of each quartile, however, was not available in that study. The Diabetes Incidence Study in Sweden reported significant association between baseline high BMI and severe NPDR and PDR ($P=0.001$), after 10 years of follow-up.⁸⁰ The EURODIAB Prospective Complications study showed increased WHR was associated with DR severity and progression in T1DM (hazard ratio: 1.3; 95%CI 1.0–1.6%, $P < 0.05$).⁸³ Even though the evidence is still equivocal between BMI and DR, it is, however, still critical for people with diabetes to maintain an optimal BMI and WHR to prevent development and progression of DR and other diabetes-related complications.

Puberty and Pregnancy

DR can worsen rapidly during puberty and pregnancy, especially in T1DM.^{84–89} In WESDR, there was a 30% excess risk of developing DR, comparing the period before and after menarche.⁸⁶ The mean time to development of DR is significantly shorter for subjects with T1DM diagnosed after puberty than for those diagnosed before puberty. (9.4 years vs 11.8 years, $P=0.0004$).⁸⁸ In WESDR, pregnancy increased the risk of DR progression by 2.3 times (adjusted OR: 2.3; $P < 0.005$).⁹⁰ Other similar studies have shown increased DR progression including development of VTDR during pregnancy.^{84,85} Severity of DR at the beginning of pregnancy has been shown to influence the risk of progression. For patients with

absent DR at baseline, DR progression in pregnancy was shown to be low.⁹¹ Of those with NPDR, 47% progressed to a more severe spectrum with 50% requiring laser treatment.⁹² During the postpartum period, 29% had regression of DR.⁹² Therefore, non-mydriatic photography should be performed for T1DM after puberty, early onset T2DM during childhood and during the course of pregnancy. For those pregnant women with PDR, they may benefit from early pan-retinal photocoagulation treatment and close review during the pregnancy and postpartum period.⁸⁵

Cataract Surgery

The ETDRS showed DR progression was associated with intra-capsular extraction and extra-capsular cataract extraction surgery.⁹³ With the adoption of the phacoemulsification surgeries, fewer patients were found to have DR progression postoperatively, compared to intra-capsular extraction or extra-capsular cataract extraction patients.⁹⁴ Pre-operative poor glycaemic control was associated with postoperative DR progression.⁹⁵ In patients with PDR, panretinal photocoagulation performed less than 6 months pre-operatively was shown to increase the risk of postoperative DME.⁹⁶ Thus, it is recommended that patients with VTDR should ideally be stabilized with panretinal photocoagulation before cataract surgery. In patients with significant cataract obscuring the fundus view, cataract surgery should be offered with postoperative surveillance of DR or DME progression.

Inflammatory Biomarkers

Chronic or low-grade inflammation and endothelial cell dysfunction are thought to play a role in the pathogenesis of DR.^{97–99} Various studies have measured the concentrations of many different inflammatory chemokines in the serum, vitreous or aqueous of patients with DR. These chemokines include prostaglandins (PGE1, PGE2), stromal cell-derived factor (SDF-1 α),¹⁰⁰ high-sensitivity C-reactive protein (hsCRP),¹⁰¹ intercellular adhesion molecule 1 (ICAM-1)¹⁰² and vascular cell adhesion molecule 1 (VCAM-1)¹⁰² and tumour necrosis factor alpha (TNF- α).¹⁰³ In DCCT study, the baseline hsCRP level may be associated with higher risk of incident CSME and macular hard exudate, and the increased ICAM-1 level was associated with the development of retinal hard exudates.¹⁰⁴ However, baseline VCAM-1 or TNF- α receptor 1 levels were not shown to be associated with risk of DR development in that study.¹⁰⁴ The markers of endothelial function can be measured using von Willebrand factor, tissue-type plasminogen activator and soluble E-selectin. Of those, the soluble E-selectin (a marker of endothelial function) was also found to

be associated with progression of retinopathy in a population-based study.⁹⁸

Genetic Risk Factors

Given the complexity of the disease, the field of genetic risk factors for DR is still in its infancy.¹⁰⁵ The attempts to identify genes in the development of DR have been limited to twin studies,¹⁰⁶ family studies,^{107–113} candidate gene studies^{114–118}, linkage studies^{109,118,119} and small-scale Genome Wide Association Study (GWAS).^{120–122} In twin studies, more concordant twins with T2DM (95%, 35 of 37) were found to have same degree of DR severity, as compared to twins with T1DM (68%, 21 of 31).¹⁰⁶ The familial aggregation studies showed that siblings or relatives of T1DM or T2DM patients with DR had up to three-fold increased risk of developing DR, compared to those with no DR.^{108–112} The heritability scores are the score used to estimate the amount of genetic influence on a particular behavior or trait by comparing how similar these different types of twins are, with 0 means that genes have no influence, and 1 being the sole influence of genes. The familial linkage is more consistently seen in the presence of more severe retinopathy, with heritability score of 0.18 to 0.27 for any DR,^{109,113} and 0.25 to 0.52 for PDR,^{108,113} in either T1DM or T2DM.

The severity and rapidity of DR onset had been associated with several genetic factors,¹²³ including chromosome 1p,¹⁰⁹ chromosomes 3 and 9,¹¹⁹ aldose reductase gene (ALR2),¹²⁴ receptor for advance glycation endproducts (RAGE) gene,¹²⁵ transforming growth factor beta 1 (TGF-beta1) gene,¹²⁶ vascular endothelial growth factor (VEGF) gene,^{127,128} endothelial nitric oxide synthase (eNOS) gene,¹²⁸ vitamin D receptor¹²⁸ and insulin-like growth factor 1 (IGF-I) gene.¹²⁹ However, these associations had been weak, inconsistent and lack of standardization of DR phenotype across different populations. It is difficult to draw any conclusions from these studies because the sample sizes of individual studies were often small. The *P* values obtained from these efforts are sometimes nominally significant but cannot withstand corrections for multiple testing. Also, the other limitation of candidate gene approach is that it depends on a priori hypothesis that implies that a particular gene has a functional explanation in DR pathophysiology, and if the hypothesis is wrong, the genetic association will be negative or inconsistent.

Linkage analysis and GWAS approaches are driven by chromosomal location without a need for any biochemical or pathophysiological association between the gene and the disease. Chromosomes 1, 3 and 12 had been linked with DR in Pima Indians and Mexican Americans.^{109,118,119} However, none of

the regions reached genome-wide statistical linkage significance. In GWAS, various single-nucleotide polymorphisms (SNPs) are had been proposed to be associated with DR traits.^{120–122,130} A single-nucleotide polymorphism is a deoxyribonucleic acid sequence variation occurring commonly within a population in which a single nucleotide – A, T, C or G – in the genome differs between members of a biological species or paired chromosomes. In one of the GWAS studies,¹²¹ DR was found to be associated with five novel chromosomal regions (chromosome 1p, 10p, 10q, 13q and 5q). Nevertheless, none of the regions reached genome-wide statistical significance. The limitations in the GWAS studies were inconsistency and low reproducibility of the single-nucleotide polymorphisms in different population, combining heterogeneous phenotypes (patients with PDR, NPDR and DME), poor characterization of health individuals (those with no DR) and poor DR standardization.

Dr Screening Programs

Early detection and prompt treatment allow prevention of up to 98% of diabetes-related visual impairment.⁶ To date, DR screening is performed in various ways by different health care professionals such as optometrists,^{131,132} GPs,^{132,133} screening technicians and clinical photographers, using direct ophthalmoscopy,¹³⁴ dilated slit lamp bio-microscopy with a hand-held lens (90 D or 78 D),¹³⁵ mydriatic or non-mydriatic retinal photography,¹³⁴ tele-retinal screening,¹³⁶ and retinal video recording (Table 2).¹³⁷ Irrespective of the screening methods, the International Council of Ophthalmology Guidelines recommend the examiners to assess patients' best-corrected visual acuity, obtain a thorough diabetes history including HbA1c (glycosylated haemoglobin), blood pressure profile, lipid profile, smoking status and other diabetes-related complications, as these risk factors may affect the urgency for referral by primary eye care providers to ophthalmologists.¹³⁸

Classification System

At present, various DR screening programs around the world use different DR classification systems.^{7,139,140} For research studies, the most commonly used retinal photography screening method is the Airlie House seven standard 30° stereoscopic fields¹³⁹, graded using the ETDRS grading system (Table 3), which consists of six levels of retinopathy for one eye or 11 levels for both eyes.¹⁴⁰ Nevertheless, this system is rather complicated to be utilized by the primary health care physicians. To simplify the DR classification system, the WHO divided the DR severity into three levels: (i) lesions that could be reviewed in the clinic in a few

Table 2. The methods, sensitivity and specificity of diabetic retinopathy (DR) screening by different practitioners^{19,135,137,147,151,192–194}

Methods of DR screening	Practitioners	Outcome measure	Sensitivity % (95% CI)	Specificity % (95% CI)	
1. Direct ophthalmoscopy ¹⁹²	GPs	Any DR	63 (56–69)	75 (70–80)	
	Optometrists	Any DR	74 (67–81)	80 (75–85)	
2. Dilated slit lamp examination ^{135,151}	GPs	Referrable DR	66 (54–77)	94 (91–96)	
	Optometrists	Referrable DR	82 (68–92)	90 (87–93)	
	Ophthalmologist	Referrable DR	87 (84–92)	95 (92–98)	
	Optometrists	Referrable DR	73 (52–88)	90 (87–93)	
3. Retinal still photography i. Mydriatic	Single field (35°) colour ¹⁹²	Any DR	79 (74–85)	73 (68–79)	
		Referrable DR	88 (83–93)	68 (62–74)	
	Two fields (50°) – Colour ¹⁵¹ (Optic disc and macula)	Any DR	73 (67–79)	93 (90–96)	
		Referrable DR	96 (87–100)	89 (86–91)	
	Two fields (50°) – Red free ¹⁵¹ (Optic disc and macula)	Any DR	93 (82–98)	87 (84–90)	
		Referrable DR	93 (82–98)	87 (84–90)	
	Three fields (30°) – Colour ¹⁹³ (Optic disc, macula and temporal)	Any DR	95 (87–98)	99 (95–99)	
		Referrable DR	92 (83–96)	96 (92–98)	
	ii. Non-mydratic	Single field (35°) – Colour ¹⁹⁴	Any DR	72 (66–79)	96 (92–99)
			Referrable DR	64 (57–71)	99 (95–100)
Single field (35°) – Red free ¹⁴⁷		Any DR	78	86	
		Referrable DR	78	86	
4. Retinal video recording – Colour ¹³⁷ (Optic disc, macula and temporal)	Ophthalmologist 1	Any DR	94 (84–98)	99 (95–99)	
	Ophthalmologist 2	Any DR	93 (83–98)	95 (89–98)	

DR, diabetic retinopathy; GPs, general practitioners.

months; (ii) lesions that need a referral as soon as possible; and (iii) sight-threatening retinopathy, which requires immediate referral.¹⁴¹ Furthermore, Wilkinson et al. published the International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales in 2003 (Table 3).¹⁴² This classification is much simpler and more user-friendly among primary eye care physicians, allowing better communication between ophthalmologists and other health care professional.

Retinal Photography

According to the UK National Institute for Clinical Excellence (NICE) guidelines, DR screening tests should have sensitivity and specificity of at least 80% and 95% respectively, with a technical failure rate of less than 5%.¹⁴³ At present, the Public Health England has published various guidelines on National Health Service diabetic eye screening programmes, with the aim to improve the DR screening in the primary health care setting. A two-field mydriatic retinal still photography, centering on (i) the optic disc and (ii) the macula, has been recommended as the preferred screening method to increase the screening accuracy and reduce the unwarranted referrals to the ophthalmologist in the tertiary eye care setting.¹⁴⁴

Mydriatic retinal photography, with additional use of ophthalmoscopy for un-gradable cases, had been shown to be the most effective DR screening

strategy.¹³⁴ It allows not only better-quality retinal images but also a minimum sensitivity of at least 80% in the detection of any grade of DR.¹⁴³ For VTDR, sensitivity and specificity increased to 97% and 92%, respectively. However, the safety of pupil dilation remains one of the fearful complications among primary eye care physicians. Nevertheless, the incidence of mydratics-induced acute angle-closure attack was reported as 6 in 20 000 Caucasians.¹⁴⁵ However, this may be higher among the Asian populations because of the difference in eye anatomy.

Non-mydratic retinal photography is a popular screening technique in the primary eye care setting, as it does not require any dilating drops. Nevertheless, the drawbacks include a higher technical failure rate resulting from media opacity or small pupils, and difficulty in obtaining stereoscopic views. In detection for VTDR requiring referrals, the sensitivity was reported between 78% and 98% with the specificity of 86% and 90%.^{146,147} It has been proven to be a cost-effective screening method to be utilized in the primary health care setting.¹⁴⁸

Recently, ultra wide-field fundus imaging technology has been implemented for DR screening. It is able to capture a 200° wide-field image in a single photograph by combining an ellipsoid mirror with a scanning laser ophthalmoscope. This technology is available in various imaging devices, including Optos (Marlborough, MA), Optomap 200Tx, Daytona imaging systems and Heidelberg Engineering (Carlsbad, CA). As compared to the

Table 3. The Proposed International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales with the corresponding levels from Early Treatment Diabetic Retinopathy Study (ETDRS), clinical findings and referral guidelines.^{7,142}

Proposed disease severity level	Clinical findings	Derivation from ETDRS levels	Management options
No apparent retinopathy	No abnormalities	Levels 10: DR absent	Optimize vascular risk factors*
Mild NPDR	MAs only	Level 20: Very mild NPDR	Optimize vascular risk factors
Moderate NPDR	More than MAs, less than severe NPDR	Levels 35,43, 47: moderate NPDR less than 4:2:1	Optimize vascular risk factors and refer to an Ophthalmologist
Severe NPDR	Any of the following (4:2:1) i. Extensive (>20) intraretinal haemorrhages in each of 4 quadrants ii. Definite venous beading in 2+ quadrants or more iii. Prominent IRMA in 1+ quadrant ore more AND no signs of PDR	53A-E: severe to very severe NPDR 4:2:1 rule	Optimize vascular risk factors, refer to an Ophthalmologist for scatter (panretinal) laser treatment
PDR	One or more of the following: i. Neovascularization ii. Vitreous/preretinal haemorrhage No apparent retinal thickening or hard exudates in posterior pole	Levels 61,65,71,75,81,85: PDR, high-risk PDR, very severe or advanced PDR	Optimize vascular risk factors, refer to an Ophthalmologist for scatter (panretinal) laser treatment Review in 1–2 years
DME apparently absent	Some apparent retinal thickening or hard exudates in posterior pole		
DME apparently present	Some retinal thickening or hard exudates in posterior pole but distant from the centre of the macula (diameter 1000 µm)		
i. Mild DME	Retinal thickening or hard exudates approaching the centre of the macula, but not involving the centre of the macula	Non-CSME	Optimize vascular risk factors and refer to an Ophthalmologist
ii. Moderate DME	Retinal thickening or hard exudates involving the centre of the macula	Non-CSME	Optimize vascular risk factors and refer to an Ophthalmologist for consideration of focal/grid lasers
iii. Severe DME		CSME i. Thickening of the retina at or within 500 µm of the centre of the macula ii. Hard exudates at or within the centre 500 µm from the centre of macula, if associated with thickening of retina iii. A zone or zones of retinal thickening 1 disc area or larger, any part of which is within 1 disc diameter of the centre of the macula	Optimize vascular risk factors and refer to an Ophthalmologist for intravitreal anti-VEGF or focal/grid lasers

CSME, clinically significant macular edema; DME, diabetic macular edema; IRMA, intraretinal microvascular abnormalities; MA, microaneurysms; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.

standard imaging, the ultra wide-field imaging was reported to improve DR diagnostic accuracy by 15% to 17% by detecting more peripheral lesions, with a lower technical failure rate of 3% and quicker image evaluation time.^{149,150} This screening modality may improve the physicians' ability to diagnose and manage diabetic eye disease, given that 10 to 15% of standard fundus images captured in multiple retinal locations is incorrect.¹⁵⁰

The technical failure rate has been reported to be higher in non-mydriatic and wide-angle field (e.g. 50°) retinal photography.^{147,151} At present, few studies have reported on the technical failure rate of screening devices, which may have an impact on the clinical- and cost-effectiveness of a screening programme. Unreadable or ungradable retinal images usually warrant mydriasis and repeat imaging either at the same session or subsequently. Failing which, the patients will warrant referrals to see ophthalmologists because of the undetermined DR state and other co-existing visually significant pathologies such as dense cataracts, rubeotic glaucoma with hazy cornea or vitreous haemorrhages.

Tele-Retinal and Mobile Eye Screening

Tele-retinal and mobile eye screening had been shown to be cost effective for DR screening in various countries including Australia, United States, United Kingdom and India.^{152–155} Tele-retinal screening involves digital retinal imaging with remote image interpretation as a means of improving access to eye care. It improves the access to DR screening service for the people who live in the rural and remote areas. In United States, a national tele-retinal imaging diabetic retinopathy screening program was set up between the Veterans Health Administration, Joslin Vision Network and the Department of Defense and the Veterans Integrated Service Network.^{155–157} Similarly, the National Health Service has also set up a National Diabetic Retinopathy Screening Program in United Kingdom with the aim to achieve a 100% screening rate for the patients with diabetes.¹⁵⁸

In Singapore, the national screening program – Singapore Diabetic Retinopathy Program had been set up using the tele-medicine model with centralized reading centre based in Singapore Eye Research Institute. This screening program provides a national coverage of 600 000 persons with diabetes with in-built quality assurance processes. The retinal still photography is interpreted within an hour by the professional graders and the report will be subsequently sent back to the primary care physicians. This program aims to minimize the patients' follow-up and to reduce the unwarranted tertiary eye care referrals. Further research may be invaluable to assess the cost-effectiveness of such programme.

MAJOR PUBLIC HEALTH CHALLENGES

Diabetes imposes a substantial public health burden. Once diagnosed with diabetes, a patient will have the disease for life. The most recent data from the International Diabetes Federation indicate that diabetes affected 387 million people worldwide in 2015, a number that is expected to grow to 592 million by 2035.⁵ In United States, the total estimated cost of diagnosed diabetes in 2012 is \$245 billion, including \$176 billion in direct medical costs and \$69 billion in reduced productivity.¹⁵⁹ The annual costs of a US diabetic population were approximately double those of matched case-controls and for those with micro- and macro-vascular complications, their costs were 3 times higher than those without.¹⁶⁰ However, savings of \$624 million and 400 000 person-years of sight could be achieved annually for United States if everyone with diabetes underwent regular diabetic retinopathy screening and received treatment according to the severity of their condition.^{161–163}

Despite having various DR screening programs, DR remains the leading cause of blindness among working-age adults in the world, ranging from 3 to 7% in the developing countries (South-East Asia and the Western Pacific region) to 15–17% in the developed regions (America and Europe).¹ Limited data is available on the cost for diabetic eye diseases. It is often difficult to segregate the eye cost from the total diabetes health-care cost, as diabetes is a metabolic disorder that affects multiple systems in people with diabetes. In US,¹⁶⁴ the direct annual cost for DR was estimated to be USD\$493 million dollars whereas in Sweden, the annual average healthcare cost of a patient with any DR, PDR and DME was reported to be USD\$93.6, USD\$334.1 and USD\$280.8, respectively.¹⁶⁵ In a recent Australian health economic report, the annual indirect costs of DME in Australia were estimated at approximately \$2.07 billion, with a significant portion of this to be because of a reduced capacity at work and lost wellbeing secondary to visual impairment.¹⁶⁶

Public education on diabetes plays an important role to raise the awareness of people with diabetes. Wang et al. reported a surprising low number of patients with diabetes (less than 50% of the survey respondents) who were aware of HbA1c,¹⁶⁷ with merely 17% understood its ideal level (<7%), significance and the physiology. Younger age and post-secondary education were shown to be significantly associated with people who understood HbA1c.¹⁶⁷ A meta-analysis also showed that the enforcement of patient education and self-management strategies reduced HbA1c levels by 0.8% compared to the control group at immediate follow-up.¹⁶⁸

To prevent diabetes and diabetic retinopathy, it is critical to educate the public on the diet and lifestyle factors, optimization of vascular risk factors (i.e. BP,

lipid, smoking), improve their awareness about diabetes and the associated complications. Lifestyle counseling in the primary care setting plays a crucial role in helping the patients with diabetes in optimization their glycaemic and other vascular risk factors control. Morrison *et al.* showed that ≥ 1 /month face-to-face counseling between the doctors and patients with diabetes (compared to less than once per 6 months) were able to enable faster achievement of HbA1c (3.5 months *vs* 22.7 months), blood pressure $< 130/85$ mmHg (3.7 weeks *vs* 5.6 months) and low-density-lipoprotein cholesterol < 100 mg/dL (3.5 months *vs* 24.7 months), with $P < 0.0001$ for all.¹⁶⁹ Furthermore, the primary health care physicians will need to be kept updated on the current DR screening and referral guidelines, ensuring early detection and prompt intervention for patients with VTDR. However, personalized education and structured interventions had recently been shown to have minimal effect on long-term HbA1c control.¹⁷⁰ This study suggests that HbA1c control still remains a substantive challenge in the real world, outside the confines of a clinical study. Further research will be invaluable to explore more alternative and effective lifestyle interventions in optimizing the glycaemic controls for these patients.

Many studies had shown that DR could be associated with patients' psychosocial well-being.^{171,172} Increased severity of DR and DME had been shown to be associated with negative impact on quality of life and depression.^{172,173} Patients with DR were more likely to have difficulty maintaining social interaction and disintegration of their social lives.¹⁷¹ They reported to have anxiety over maintaining friendships or acquaintances, or meeting new people because of difficulty recognizing faces.^{171,174,175} Younger patients with DR found visual impairment as a major deterrent to finding potential partners and forming romantic relationships.¹⁷¹ Moreover, visual impairment secondary to DR could also result in unemployment and loss of income.¹⁷¹

Non-adherence to medication, a common problem for patients with diabetes, is associated with poor glycaemic control, increased risk for hospitalization and mortality.¹⁷⁶ Increasingly, cognitive behavioural therapy (CBT), combined with a series of diabetes self-management and adherence interventions, has been shown to be an effective intervention for people with diabetes.^{173,177} The people with diabetes who underwent a total of 12 sessions of CBT consisting of different modules are 27% and 30.2% more adherent to the oral medication and self-monitoring of blood glucose, respectively ($P = 0.000$) and has lower HbA1c by 0.6 units ($P = 0.03$) than the non-CBT group.¹⁷³

Prevention of diabetes-related visual impairment

Early detection is crucial to prevent diabetes-related visual impairment. Primary prevention could be undertaken to prevent the occurrence of diabetes by raising the public awareness to avoid obesity, increase physical activity and to consume low fat/high complex carbohydrate diet.¹⁷⁸ All of these strategies had been shown to increase insulin sensitivity and reduce the prevalence of diabetes in the general population.^{179,180}

However, it is rather challenging to prevent the development of diabetes with the primary prevention as mentioned earlier. Once patients develop diabetes, secondary prevention should then focus on maintaining good glycaemic control, optimization of vascular risk factors (e.g. hypertension, hyperlipidemia, cessation of smoking) and ensuring early eye screening.¹⁷⁸ Failing which, these patients with poor glycaemic control will develop vision-threatening DR (severe NPDR and PDR), requiring prompt scattered retinal laser to prevent blinding complications.^{181,182} At present, research and clinical resources are heavily invested on the VTDR area. More focus and resources should be redirected to the research related to primary and secondary prevention in order to reduce the permanent visual loss secondary to diabetes.

A successful DR screening program involves various factors including high sustainability and accessibility of the screening service in the community with highly trained health providers in DR screening.^{144,183,184} The National Health Service has set out operational guidance (e.g. screening settings, role definition of clinical leads, standardization of grading thresholds, equipment guidance, photographic methods, referral intervals) for diabetic eye screening program in England.¹⁸⁵ It is also crucial to evaluate the health economic data on the cost-effectiveness of various different business models for a screening program, based on the existing infrastructure and clinical service.¹⁸⁶ Tele-retinal screening, using digital photography with telemedicine links, has been shown to be a cost-effective method to improve early access of DR screening services to rural, remote and hard-to-reach populations.¹⁸⁷ Scattered delivery systems may be transformed into a comprehensive DR network. This enables the capitalization of the resources, tools and training available in urban areas.

Globally, there is a mismatch between the capacity to implement DR screening services *versus* the number of people with diabetes, especially in the low and middle-income countries. Retinal still photography, mydriatic and non-mydriatic, has been shown to be the cost-effective DR screening strategy.^{148,188} The cost-effectiveness of a screening program is sensitive to the program size because of high fixed cost of the camera methods, but not to prevalence.¹⁸⁸ For the resource-rich developed countries, further research

should also be directed to evaluate interventions for DME, in addition to prevent visual loss from PDR.^{181,189} For the management of fovea-involving DME, anti-vascular endothelial growth factor (aflibercept, ranibizumab or bevacizumab) has become the primary treatment to improve vision.^{189,190}

More resources should be directed towards exploring more alternative novel therapeutics for DR and DME. On the other hand, the fundamental problems of the resource-poor low to middle income countries are the lack of access to high-quality ophthalmologists and limited health care resources such as the lasers machines and anti-VEGF therapy.¹⁹¹ It is, therefore, extremely crucial to channel the finite resources to develop innovative strategies to improve the disease awareness and access to the screening services and treatment in these countries.¹⁸⁸ The overall cost-effectiveness of a screening program is influenced by variation in compliance rates, age of onset of diabetes, glycaemic control and screening sensitivities.¹⁸⁶

CONCLUSION

Diabetes retinopathy (DR) remains a global health issue. Early detection and prompt treatment allow prevention of diabetes-related visual impairment. Patients with diabetes require regular follow-up with primary care physicians to optimize their glycaemic, blood pressure and lipid control to prevent development and progression of DR and other diabetes-related complications. In spite of the major understanding of epidemiology and risk factors of DR, more research is required to the awareness of DR among the people with diabetes. A better understanding of the type and extent of the psychosocial impact of DR may assist policy planners and rehabilitation workers to improve quality of life for patients with diabetes. With the rising incidence and prevalence of diabetes and DR, it is challenging to maintain the costs and running of DR screening programs for people with diabetes. To reduce the impact of DR-related visual loss, it is important that all stakeholders continue to look for innovative ways of managing and preventing diabetes, and optimize cost-effective screening programs within the community.

REFERENCES

- Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. *Ophthalmology* 1998; **105**: 998–1003.
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes care* 2004; **27**: 1047–53.
- Klein BE. Overview of epidemiologic studies of diabetic retinopathy. *Ophthalmic epidemiology* 2007; **14**: 179–83.
- Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet* 2010; **376** (9735): 124–36.
- International Diabetes Federation. Diabetes atlas, 6th ed, Brussels, Belgium. 2015.
- Ferris FL 3rd.. How effective are treatments for diabetic retinopathy? *Jama* 1993; **269**: 1290–1.
- Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. *Ophthalmology* 1991; **98**: 786–806.
- James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. *BMJ* 2000; **320**: 1627–31.
- Resnikoff S, Pascolini D, Etya'ale D, *et al.* Global data on visual impairment in the year 2002. *Bulletin of the World Health Organization* 2004; **82**: 844–51.
- Yau JW, Rogers SL, Kawasaki R, *et al.* Global prevalence and major risk factors of diabetic retinopathy. *Diabetes care* 2012; **35**: 556–64.
- Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. *Survey of ophthalmology* 2012; **57**: 347–70.
- Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. *Diabetologia* 1994; **37**: 278–85.
- Roy MS, Klein R, O'Colmain BJ, Klein BE, Moss SE, Kempen JH. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. *Archives of ophthalmology* 2004; **122**: 546–51.
- Ramachandran A, Snehalatha C, Sasikala R, Satyavani K, Vijay V. Vascular complications in young Asian Indian patients with type 1 diabetes mellitus. *Diabetes research and clinical practice* 2000; **48**: 51–6.
- Ko GT, Chan JC, Lau M, Cockram CS. Diabetic microangiopathic complications in young Chinese diabetic patients: a clinic-based cross-sectional study. *Journal of diabetes and its complications* 1999; **13**: 300–6.
- Bonney M, Hing SJ, Fung AT, *et al.* Development and progression of diabetic retinopathy: adolescents at risk. *Diabetic medicine: a journal of the British Diabetic Association* 1995; **12**: 967–73.
- Fairchild JM, Hing SJ, Donaghue KC, *et al.* Prevalence and risk factors for retinopathy in adolescents with type 1 diabetes. *Med J Aust* 1994; **160**: 757–62.
- Scott A, Whitcombe S, Bouchier D, Dunn P. Diabetes in children and young adults in Waikato Province, New Zealand: outcomes of care. *N Z Med J* 2004; **117**: U1219.
- Maguire A, Chan A, Cusumano J, *et al.* The case for biennial retinopathy screening in children and adolescents. *Diabetes care* 2005; **28**: 509–13.
- Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. *Ophthalmology* 1995; **102**: 7–16.
- Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in

- patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. *The Lancet* 2003; **361**: 195–200.
22. Stratton IM, Kohner EM, Aldington SJ, *et al.* UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. *Diabetologia* 2001; **44**: 156–63.
 23. Giuffrè G, Lodato G, Dardanoni G. Prevalence and risk factors of diabetic retinopathy in adult and elderly subjects: The Casteldaccia Eye Study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle. *Ophthalmologie* 2004; **242**: 535–40.
 24. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Aarhus County, Denmark. *Acta ophthalmologica Scandinavica* 2004; **82**: 443–8.
 25. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The North Jutland County Diabetic Retinopathy Study: population characteristics. *Br J Ophthalmol* 2006; **90**: 1404–9.
 26. Hamman RF, Mayer EJ, Moo-Young GA, Hildebrandt W, Marshall JA, Baxter J. Prevalence and risk factors of diabetic retinopathy in non-Hispanic whites and Hispanics with NIDDM. *San Luis Valley Diabetes Study. Diabetes* 1989; **38**: 1231–7.
 27. Varma R, Ying-Lai M, Klein R, Azen SP. Los Angeles Latino Eye Study G. Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study. *Ophthalmology* 2004; **111**: 1132–40.
 28. Wong TY, Klein R, Islam FM, *et al.* Diabetic retinopathy in a multi-ethnic cohort in the United States. *American journal of ophthalmology* 2006; **141**: 446–55.
 29. Emanuele N, Sacks J, Klein R, *et al.* Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. *Diabetes care* 2005; **28**: 1954–8.
 30. Varma R, Paz SH, Azen SP, *et al.* The Los Angeles Latino Eye Study: design, methods, and baseline data. *Ophthalmology* 2004; **111**: 1121–31.
 31. Tapp RJ, Shaw JE, Harper CA, *et al.* The prevalence of and factors associated with diabetic retinopathy in the Australian population. *Diabetes care* 2003; **26**: 1731–7.
 32. Mitchell P, Smith W, Wang JJ, Attebo K. Prevalence of diabetic retinopathy in an older community. *The Blue Mountains Eye Study. Ophthalmology* 1998; **105**: 406–11.
 33. McKay R, McCarty CA, Taylor HR. Diabetic retinopathy in Victoria, Australia: the Visual Impairment Project. *British journal of ophthalmology* 2000; **84**: 865–70.
 34. Mitchell P, Moffitt PS, Beaumont P. Prevalence of vision-threatening diabetic retinopathy in Newcastle, Australia. *Tohoku J Exp Med* 1983; **141**: 379–83.
 35. Mitchell P. Development and progression of diabetic eye disease in Newcastle (1977–1984): rates and risk factors. *Australian and New Zealand journal of ophthalmology* 1985; **13**: 39–44.
 36. He S, Guo Y, Li Z. Epidemiologic study of diabetic retinopathy in Capital Steel Company]. [Zhonghua yan ke za zhi. *Chinese journal of ophthalmology* 1997; **33**: 381–3.
 37. Raman R, Rani PK, Reddi Racheppalle S, *et al.* Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. *Ophthalmology* 2009; **116**: 311–8.
 38. Wang FH, Liang YB, Zhang F, *et al.* Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. *Ophthalmology* 2009; **116**: 461–7.
 39. Xie XW, Xu L, Wang YX, Jonas JB. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefe's archive for clinical and experimental ophthalmology. *Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie* 2008; **246**: 1519–26.
 40. Raman R, Ganesan S, Pal SS, Kulothungan V, Sharma T. Prevalence and risk factors for diabetic retinopathy in rural India. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study III (SN-DREAMS III), report no 2. *BMJ open diabetes research & care* 2014; **2**: e000005.
 41. Chiang PP, Lamoureux EL, Cheung CY, *et al.* Racial differences in the prevalence of diabetes but not diabetic retinopathy in a multi-ethnic Asian population. *Investigative ophthalmology & visual science* 2011; **52**: 7586–92.
 42. Zheng Y, Lamoureux EL, Lavanya R, *et al.* Prevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. *Ophthalmology* 2012; **119**: 2119–24.
 43. Burger W, Hovener G, Dusterhus R, Hartmann R, Weber B. Prevalence and development of retinopathy in children and adolescents with type 1 (insulin-dependent) diabetes mellitus. A longitudinal study. *Diabetologia* 1986; **29**: 17–22.
 44. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. *Ophthalmology* 2008; **115**: 1859–68.
 45. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. *Ophthalmology* 2009; **116**: 497–503.
 46. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. *Diabetes care* 2012; **35**: 592–6.
 47. Leske MC, Wu SY, Hennis A, *et al.* Incidence of diabetic retinopathy in the Barbados Eye Studies. *Ophthalmology* 2003; **110**: 941–7.
 48. Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. *Eye (Lond)* 2007; **21**: 465–71.
 49. Song H, Liu L, Sum R, Fung M, Yap MK. Incidence of diabetic retinopathy in a Hong Kong Chinese population. *Clinical & experimental optometry: journal of the Australian Optometrical Association* 2011; **94**: 563–7.

50. Wong TY, Mwamburi M, Klein R, *et al.* Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. *Diabetes care* 2009; **32**: 2307–13.
51. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *The New England journal of medicine* 1993; **329**: 977–86.
52. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. *Ophthalmology* 1995; **102**: 647–61.
53. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. *The New England journal of medicine* 2000; **342**: 381–9.
54. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998; **352**: 837–53.
55. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. *Jama* 2007; **298**: 902–16.
56. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *The New England journal of medicine* 2008; **359**: 1577–89.
57. Drzewoski J, Kasznicki J, Trojanowski Z. The role of “metabolic memory” in the natural history of diabetes mellitus. *Pol Arch Med Wewn* 2009; **119** (7–8): 493–500.
58. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. *Archives of ophthalmology* 1998; **116**: 874–86.
59. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. *Lancet* 1993; **341**: 1306–9.
60. Group AS, Group AES, Chew EY, *et al.* Effects of medical therapies on retinopathy progression in type 2 diabetes. *The New England journal of medicine* 2010; **363**: 233–44.
61. Zoungas S, Chalmers J, Ninomiya T, *et al.* Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. *Diabetologia* 2012; **55**: 636–43.
62. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema. *Ophthalmology* 1989; **96**: 1501–10.
63. Wong TY, Mitchell P. The eye in hypertension. *Lancet* 2007; **369**: 425–35.
64. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? *Archives of internal medicine* 1989; **149**: 2427–32.
65. Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. *Lancet* 2008; **372**: 1361–3.
66. Chaturvedi N, Porta M, Klein R, *et al.* Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. *Lancet* 2008; **372**: 1394–402.
67. Mauer M, Zinman B, Gardiner R, *et al.* Renal and retinal effects of enalapril and losartan in type 1 diabetes. *The New England journal of medicine* 2009; **361**: 40–51.
68. Sjolie AK, Klein R, Porta M, *et al.* Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. *Lancet* 2008; **372**: 1385–93.
69. Mauer M, Zinman B, Gardiner R, *et al.* ACE-I and ARBs in early diabetic nephropathy. *Journal of the renin-angiotensin-aldosterone system: JRAAS* 2002; **3**: 262–9.
70. Chaturvedi N, Sjolie AK, Stephenson JM, *et al.* Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. *Lancet* 1998; **351**(9095): 28–31.
71. Schrier RW, Savage S. Appropriate blood pressure control in type II diabetes (ABCD Trial): implications for complications. *Am J Kidney Dis* 1992; **20**: 653–7.
72. Wong TY, Cheung N, Tay WT, *et al.* Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. *Ophthalmology* 2008; **115**: 1869–75.
73. Raman R, Rani PK, Kulothungan V, Rachevalle SR, Kumaramanickavel G, Sharma T. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. *Ophthalmology* 2010; **117**: 766–72.
74. Rema M, Srivastava BK, Anitha B, Deepa R, Mohan V. Association of serum lipids with diabetic retinopathy in urban South Indians – the Chennai Urban Rural Epidemiology Study (CURES) Eye Study – 2. *Diabetic medicine: a journal of the British Diabetic Association* 2006; **23**: 1029–36.
75. Lyons TJ, Jenkins AJ, Zheng D, *et al.* Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. *Investigative ophthalmology & visual science* 2004; **45**: 910–8.
76. Keech AC MP, Summanen PA, *et al.* . Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. *Lancet* 2007; **370**: 1687–97.
77. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. *Archives of ophthalmology* 1984; **102**: 520–6.
78. Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Archives of internal medicine* 1997; **157**: 650–6.
79. Lim LS, Tai ES, Mitchell P, *et al.* C-reactive protein, body mass index, and diabetic retinopathy. *Investigative ophthalmology & visual science* 2010; **51**: 4458–63.
80. Henricsson M, Nystrom L, Blohme G, *et al.* The incidence of retinopathy 10 years after diagnosis in young

- adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). *Diabetes care* 2003; **26**: 349–54.
81. Chaturvedi N, Sjoelie AK, Porta M, *et al.* Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. *Diabetes care* 2001; **24**: 284–9.
 82. van Hecke MV, Dekker JM, Stehouwer CD, *et al.* Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. *Diabetes care* 2005; **28**: 1383–9.
 83. Soedamah-Muthu SS, Chaturvedi N, Toeller M, *et al.* Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. *Diabetes care* 2004; **27**: 530–7.
 84. Vestgaard M, Ringholm L, Laugesen CS, Rasmussen KL, Damm P, Mathiesen ER. Pregnancy-induced sight-threatening diabetic retinopathy in women with Type 1 diabetes. *Diabetic medicine: a journal of the British Diabetic Association* 2010; **27**: 431–5.
 85. Rasmussen KL, Laugesen CS, Ringholm L, Vestgaard M, Damm P, Mathiesen ER. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. *Diabetologia* 2010; **53**: 1076–83.
 86. Klein BE, Moss SE, Klein R. Is menarche associated with diabetic retinopathy? *Diabetes care* 1990; **13**: 1034–8.
 87. Donaghue KC, Fairchild JM, Craig ME, *et al.* Do all prepubertal years of diabetes duration contribute equally to diabetes complications? *Diabetes care* 2003; **26**: 1224–9.
 88. Olsen BS, Sjolie AK, Hougaard P, *et al.* The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. *Journal of diabetes and its complications* 2004; **18**: 160–4.
 89. Diabetes C. Complications Trial Research G. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. *Diabetes care* 2000; **23**: 1084–91.
 90. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. *Diabetes care* 1990; **13**: 34–40.
 91. Stalnikiiewicz L, Floriot M, Guerci B, Angioi K. Progression of diabetic retinopathy during pregnancy: a retrospective analysis of a series of 77 consecutive patients. *Journal francais d'ophtalmologie* 2010; **33**: 481–6.
 92. Sunness JS. The pregnant woman's eye. *Survey of ophthalmology* 1988; **32**: 219–38.
 93. Chew EY, Benson WE, Remaley NA, *et al.* Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. *Archives of ophthalmology* 1999; **117**: 1600–6.
 94. Shah AS, Chen SH. Cataract surgery and diabetes. *Current opinion in ophthalmology* 2010; **21**: 4–9.
 95. Henricsson M, Heijl A, Janzon L. Diabetic retinopathy before and after cataract surgery. *Br J Ophthalmol* 1996; **80**: 789–93.
 96. Suto C, Kitano S, Hori S. Optimal timing of cataract surgery and panretinal photocoagulation for diabetic retinopathy. *Diabetes care* 2011; **34**: e123.
 97. Lim LS, Wong TY. Lipids and diabetic retinopathy. *Expert opinion on biological therapy* 2012; **12**: 93–105.
 98. Spijkerman AM, Gall MA, Tarnow L, *et al.* Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. *Diabetic medicine: a journal of the British Diabetic Association* 2007; **24**: 969–76.
 99. van Hecke MV, Dekker JM, Nijpels G, *et al.* Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. *Diabetologia* 2005; **48**: 1300–6.
 100. Meleth AD, Agron E, Chan CC, *et al.* Serum inflammatory markers in diabetic retinopathy. *Investigative ophthalmology & visual science* 2005; **46**: 4295–301.
 101. Nowak M, Wielkoszynski T, Marek B, *et al.* Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. *Clinical and experimental medicine* 2010; **10**: 185–92.
 102. Nowak M, Wielkoszynski T, Marek B, *et al.* Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. *Clinical and experimental medicine* 2008; **8**: 159–64.
 103. Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. *Journal of diabetes and its complications* 2008; **22**: 309–16.
 104. Muni RH, Kohly RP, Lee EQ, Manson JE, Semba RD, Schaumberg DA. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. *JAMA ophthalmology* 2013; **131**: 514–21.
 105. Kuo JZ, Wong TY, Rotter JI. Challenges in elucidating the genetics of diabetic retinopathy. *JAMA ophthalmology* 2014; **132**: 96–107.
 106. Leslie RD, Pyke DA. Diabetic retinopathy in identical twins. *Diabetes* 1982; **31**: 19–21.
 107. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. *Diabetes* 1997; **46**(11): 1829–39.
 108. Hietala K, Forsblom C, Summanen P, Groop PH, FinnDiane SG. Heritability of proliferative diabetic retinopathy. *Diabetes* 2008; **57**: 2176–80.
 109. Looker HC, Nelson RG, Chew E, *et al.* Genome-wide linkage analyses to identify Loci for diabetic retinopathy. *Diabetes* 2007; **56**: 1160–6.
 110. Zhang X, Gao Y, Zhou Z, Wang J, Zhou Q, Li Q. Familial clustering of diabetic retinopathy in Chongqing, China, type 2 diabetic patients. *European journal of ophthalmology* 2010; **20**: 911–8.
 111. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian Type 2 diabetic patients. *Diabetic medicine: a journal of the British Diabetic Association* 2002; **19**: 910–6.
 112. Hallman DM, Huber JC Jr, Gonzalez VH, Klein BE, Klein R, Hanis CL. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. *Diabetes care* 2005; **28**: 1163–8.

113. Arar NH, Freedman BI, Adler SG, *et al.* Heritability of the severity of diabetic retinopathy: the FIND-Eye study. *Investigative ophthalmology & visual science* 2008; **49**: 3839–45.
114. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. *International ophthalmology clinics* 2009; **49**: 35–52.
115. Ng DP. Human genetics of diabetic retinopathy: current perspectives. *Journal of ophthalmology* 2010; **2010**.
116. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. *Diabetes* 2009; **58**: 2137–47.
117. Zhao T, Zhao J. Association between the –634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis. *Diabetes research and clinical practice* 2010; **90**: 45–53.
118. Hallman DM, Boerwinkle E, Gonzalez VH, Klein BE, Klein R, Hanis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas. *Diabetes* 2007; **56**: 1167–73.
119. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. *Pima Diabetes Genes Group. Diabetes* 1998; **47**: 821–30.
120. Fu YP, Hallman DM, Gonzalez VH, *et al.* Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from Starr County, Texas. *Journal of ophthalmology* 2010; **2010**.
121. Huang YC, Lin JM, Lin HJ, *et al.* Genome-wide association study of diabetic retinopathy in a Taiwanese population. *Ophthalmology* 2011; **118**: 642–8.
122. Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. Genome-wide meta-analysis for severe diabetic retinopathy. *Hum Mol Genet* 2011; **20**: 2472–81.
123. Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. *Ophthalmic genetics* 2003; **24**: 41–8.
124. Olmos P, Bastias MJ, Vollrath V, *et al.* C(–106)T polymorphism of the aldose reductase gene and the progression rate of diabetic retinopathy. *Diabetes research and clinical practice* 2006; **74**: 175–82.
125. Kumaramanickavel G, Ramprasad VL, Sripriya S, Upadyay NK, Paul PG, Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. *Journal of diabetes and its complications* 2002; **16**: 391–4.
126. Beranek M, Kankova K, Benes P, *et al.* Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy. *American journal of medical genetics* 2002; **109**: 278–83.
127. Errera FI, Canani LH, Silva ME, *et al.* Functional vascular endothelial growth factor –634G > C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry. *Diabetes care* 2007; **30**: 275–9.
128. Suganthalakshmi B, Anand R, Kim R, *et al.* Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. *Molecular vision* 2006; **12**: 336–41.
129. Rietveld I, Ikram MK, Vingerling JR, *et al.* An igf-I gene polymorphism modifies the risk of diabetic retinopathy. *Diabetes* 2006; **55**: 2387–91.
130. Sheu WH, Kuo JZ, Lee IT, *et al.* Genome-wide association study in a Chinese population with diabetic retinopathy. *Hum Mol Genet* 2013; **22**: 3165–73.
131. Hammond C, Shackleton J, Flanagan DW, Herrtage J, Wade J. Comparison between an ophthalmic optician and ophthalmologist in screening for diabetic retinopathy. *Eye* 1996; **107**–12.
132. Buxton M, Sculpher MJ, Ferguson BA *et al.* Screening for treatable diabetic retinopathy: a comparison of different methods. *DiabetMed* 1991; **8**: 371–7.
133. Lienert R. Inter-observer comparisons of ophthalmoscopic assessment of diabetic retinopathy. *AustNZJ Ophthalmol* 1989; **17**: 363–8.
134. Hutchinson A, McIntosh A, Peters J, *et al.* Effectiveness of screening and monitoring tests for diabetic retinopathy – a systematic review. *Diabetic medicine: a journal of the British Diabetic Association* 2000; **17**: 495–506.
135. Scanlon PH, Malhotra R, Greenwood RH, *et al.* Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. *Br J Ophthalmol* 2003; **87**: 1258–63.
136. Murray R, Metcalf SM, Lewis PM, Mein JK, McAllister IL. Sustaining remote-area programs: retinal camera use by Aboriginal health workers and nurses in a Kimberley partnership. *MedJ Aust* 2005; **182**: 520–3.
137. Ting DS, Tay-Kearney ML, Constable I, Lim L, Preen DB, Kanagasalingam Y. Retinal video recording a new way to image and diagnose diabetic retinopathy. *Ophthalmology* 2011; **118**: 1588–93.
138. International Council of Ophthalmology. Diabetic Eye Care. ICO Guidelines for Diabetic Eye Care. 2014. <http://www.icoph.org/taskforce-documents/diabetic-retinopathy-guidelines.html>.
139. Goldberg M, Fine S. Symposium on the Treatment of Diabetic Retinopathy, Airlie House, Warrenton, Virginia.: Department of Health, Education and Welfare.; 1968.
140. Davis MD, Hubbard LD, Trautman J, Klein R. Conference on insulin pump therapy in diabetes. Multicenter study effect on microvascular disease. Studies of retinopathy. Methodology for assessment and classification with fundus photographs. *Diabetes* 1985; **34 Suppl 3**: 42–9.
141. Kohner EPM. *Screening for diabetic retinopathy: A field guide-book*, 1992.
142. Wilkinson CP, Ferris FL 3rd, Klein RE, *et al.* Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology* 2003; **110**: 1677–82.
143. National Institute for Clinical Excellence. Diabetic retinopathy – early management and screening. London, UK 2001.

144. Scanlon PH. The English national screening programme for sight-threatening diabetic retinopathy. *J Med Screen* 2008; **15**: 1–4.
145. Liew G, Mitchell P, Wang JJ, Wong TY. Fundoscopy: to dilate or not to dilate? *BMJ* 2006; **332**: 3.
146. Fransen S, Leonard-Martin TC, Feuer WJ, Hildebrand PL. Clinical evaluation of patients with diabetic retinopathy: accuracy of the Inoveon diabetic retinopathy-3DT system. *Ophthalmology* 2002; **109**: 595–601.
147. Lin D, Blumenkranz M, Brothers R, Grosvenor D. The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. *American journal of ophthalmology* 2002; **134**: 204–13.
148. Khan T, Bertram MY, Jina R, Mash B, Levitt N, Hofman K. Preventing diabetes blindness: cost effectiveness of a screening programme using digital non-mydriatic fundus photography for diabetic retinopathy in a primary health care setting in South Africa. *Diabetes research and clinical practice* 2013; **101**: 170–6.
149. Silva PS, Cavallerano JD, Tolls D, *et al.* Potential efficiency benefits of nonmydriatic ultrawide field retinal imaging in an ocular telehealth diabetic retinopathy program. *Diabetes care* 2014; **37**: 50–5.
150. Wessel MM, Aaker GD, Parlitsis G, Cho M, D'Amico DJ, Kiss S. Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. *Retina* 2012; **32**: 785–91.
151. Olson JA, Strachan FM, Hipwell JH, *et al.* A comparative evaluation of digital imaging, retinal photography and optometrist examination in screening for diabetic retinopathy. *Diabetic medicine: a journal of the British Diabetic Association* 2003; **20**: 528–34.
152. Kumar S, Tay-Kearney ML, Constable IJ, Yogesan K. Internet based ophthalmology service: impact assessment. *The British journal of ophthalmology* 2005; **89**: 1382–3.
153. Kumar S, Tay-Kearney ML, Chaves F, Constable IJ, Yogesan K. Remote ophthalmology services: cost comparison of telemedicine and alternative service delivery options. *J Telemed Telecare* 2006; **12**: 10–22.
154. Sharma M, Chakrabarty AS, Pavan R, Sharma R, Pratibha G. An integrated, mobile service for diabetic retinopathy in rural India. *Community eye health / International Centre for Eye Health* 2011; **24**: 17–8.
155. Bursell SE, Cavallerano JD, Cavallerano AA, *et al.* Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. *Ophthalmology* 2001; **108**: 572–85.
156. Conlin PR, Fisch BM, Orcutt JC, Hetrick BJ, Darkins AW. Framework for a national teleretinal imaging program to screen for diabetic retinopathy in Veterans Health Administration patients. *J Rehabil Res Dev* 2006; **43**: 741–8.
157. Cavallerano AA, Cavallerano JD, Katalinic P, *et al.* A telemedicine program for diabetic retinopathy in a Veterans Affairs Medical Center – the Joslin Vision Network Eye Health Care Model. *American journal of ophthalmology* 2005; **139**: 597–604.
158. National Health Service (NHS). National Screening Programme for Diabetic Retinopathy.
159. American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2012. *Diabetes care*: 1–11.
160. Raikou M, McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. *Pharmacoeconomics* 2003; **21**: 543–64.
161. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. *Diabetes care* 1994; **17**: 909–17.
162. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type I diabetes mellitus. Savings associated with improved implementation of current guidelines. *American Academy of Ophthalmology. Ophthalmology* 1991; **98**: 1565–73 discussion 74.
163. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. *Annals of internal medicine* 1996; **124**: 164–9.
164. Rein DB, Zhang P, Wirth KE, *et al.* The economic burden of major adult visual disorders in the United States. *Archives of ophthalmology* 2006; **124**: 1754–60.
165. Heintz E, Wirehn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. *Diabetologia* 2010; **53**: 2147–54.
166. Australia D. *The Economic Impact of Diabetic Macular Oedema in Australia*, 2015.
167. Wang S, Tikellis G, Wong N, Wong TY, Wang JJ. Lack of knowledge of glycosylated hemoglobin in patients with diabetic retinopathy. *Diabetes research and clinical practice* 2008; **81**: e15–7.
168. Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. *Diabetes care* 2002; **25**: 1159–71.
169. Morrison F, Shubina M, Turchin A. Lifestyle counseling in routine care and long-term glucose, blood pressure, and cholesterol control in patients with diabetes. *Diabetes care* 2012; **35**: 334–41.
170. Aiello LP, Ayala AR, Antoszyk AN, *et al.* Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. *JAMA ophthalmology* 2015; **133**: 888–96.
171. Fenwick E, Rees G, Pesudovs K, *et al.* Social and emotional impact of diabetic retinopathy: a review. *Clinical & experimental ophthalmology* 2012; **40**: 27–38.
172. Fenwick EK, Pesudovs K, Rees G, *et al.* The impact of diabetic retinopathy: understanding the patient's perspective. *Br J Ophthalmol* 2011; **95**: 774–82.
173. Safren SA, Gonzalez JS, Wexler DJ, *et al.* A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes. *Diabetes care* 2014; **37**: 625–33.
174. Cox DJ, Kiernan BD, Schroeder DB, Cowley M. Psychosocial sequelae of visual loss in diabetes. *Diabetes Educ* 1998; **24**: 481–4.

175. Trento M, Tomelini M, Lattanzio R, *et al.* Perception of, and anxiety levels induced by, laser treatment in patients with sight-threatening diabetic retinopathy. A multicentre study. *Diabetic medicine: a journal of the British Diabetic Association* 2006; **23**: 1106–9.
176. Ho PM, Rumsfeld JS, Masoudi FA, *et al.* Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. *Archives of internal medicine* 2006; **166**: 1836–41.
177. Serlachius AS, Scratch SE, Northam EA, Frydenberg E, Lee KJ, Cameron FJ. A randomized controlled trial of cognitive behaviour therapy to improve glycaemic control and psychosocial wellbeing in adolescents with type 1 diabetes. *J Health Psychol* 2014.
178. Dornhorst A, Merrin PK. Primary, secondary and tertiary prevention of non-insulin-dependent diabetes. *Postgraduate medical journal* 1994; **70**: 529–35.
179. Balkau B, Mhamdi L, Oppert JM, *et al.* Physical activity and insulin sensitivity: the RISC study. *Diabetes* 2008; **57**: 2613–8.
180. Bessesen DH. The role of carbohydrates in insulin resistance. *J Nutr* 2001; **131**: 2782S–6S.
181. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. *Ophthalmology* 1981; **88**: 583–600.
182. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. *Archives of ophthalmology* 1985; **103**: 1644–52.
183. Harding S, Greenwood R, Aldington S, *et al.* Grading and disease management in national screening for diabetic retinopathy in England and Wales. *Diabetic medicine: a journal of the British Diabetic Association* 2003; **20**: 965–71.
184. Scanlon PH, Aldington SJ, Leal J, *et al.* Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. *Health Technol Assess* 2015; **19**: 1–116.
185. National Health Service, England, United Kingdom. Diabetic eye screening: commission and provide. 2015.
186. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. *Diabetic medicine: a journal of the British Diabetic Association* 2010; **27**: 249–56.
187. Rachapelle S, Legood R, Alavi Y, *et al.* The cost-utility of telemedicine to screen for diabetic retinopathy in India. *Ophthalmology* 2013; **120**: 566–73.
188. Lairson DR, Pugh JA, Kapadia AS, Lorimor RJ, Jacobson J, Velez R. Cost-effectiveness of alternative methods for diabetic retinopathy screening. *Diabetes care* 1992; **15**: 1369–77.
189. Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, *et al.* Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *The New England journal of medicine* 2015; **372**: 1193–203.
190. Diabetic Retinopathy Clinical Research N, Elman MJ, Aiello LP, *et al.* Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2010; **117**: 1064–77 e35.
191. Xu H. P. Z. Present condition of ophthalmology resource in China in 2000. *Medicine and Society* 2005; **18**: 7–9.
192. Gibbins RL, Owens DR, Allen JC, Eastman L. Practical application of the European Field Guide in screening for diabetic retinopathy by using ophthalmoscopy and 35 mm retinal slides. *Diabetologia* 1998; **41**: 59–64.
193. Ting DS, Tay-Kearney ML, Kanagasingam Y. Light and portable novel device for diabetic retinopathy screening. *Clinical & experimental ophthalmology* 2012; **40**: e40–6.
194. Pugh JA, Jacobson JM, Van Heuven WA, *et al.* Screening for diabetic retinopathy. The wide-angle retinal camera. *Diabetes care* 1993; **16**: 889–95.